THE DIRECT COSTS ASSOCIATED WITH POSTERIOR CAPSULE OPACIFICATION IN THE NETHERLANDS- A PAYER PERSPECTIVE

Author(s)

Bosgra OJ1, Busutil R2, de Ruiter L3, Perez Vives C4, O'Boyle D5
1Alcon Nederland BV, Doorn, UT, Netherlands, 2Alcon Healthcare, S.A., Barcelona, AP, Spain, 3Alcon Nederland BV, Gorinchem, Netherlands, 4Alcon Management SA, Geneva, Switzerland, 5Alcon Laboratories Ireland Ltd, Cork, CO, Ireland

OBJECTIVES

Cataract surgery is the most frequently performed surgical procedure in the Netherlands and posterior capsule opacification (PCO) is the most common complication post-surgery. Nd:YAG capsulotomy is the standard of care for treating PCO, although it bears a cost and is also associated with complications. PCO development is heavily dependent on the choice of intraocular lens (IOL) for cataract surgery and AcrySof IOLs have consistently demonstrated lower Nd:YAG rates compared to other IOLs, with 1 and 3 year estimates reported as low as 0.6% and 2.4%, respectively. The objective of this research was to estimate annual direct costs associated with the treatment of PCO in the Netherlands.

METHODS

A cost-consequence model was developed comparing healthcare resource utilization and costs associated with PCO. An estimate for the rate of Nd:YAG capsulotomy in the Netherlands was derived from publicaly available statistics (29%), as was estimates for the number of cataract surgeries performed annually (158,415). Cost categories such as associated follow-up consultations (1-per Nd:YAG procedure) and associated (1-year) clinical complications were attained from the published literature. Costs were based on average national tariffs in 2017. Sensitivities of -20% and +20% were applied to PCO associated costs.

RESULTS

For the year 2017, we estimate 45,940 Nd:YAG capsulotomy were procedures performed to treat PCO in the Netherlands. Frequencies of subsequent follow-up consultations (45,940) and cases of clinical complications (RD: 381; CME: 2,733 & Glaucoma: 1,392) were estimated. Total direct costs associated with treating PCO were estimated as being in the region of €12.9 to €19.4 million.

CONCLUSIONS

The total annual direct costs associated with treating PCO in the Netherlands was estimated as being in the region of €12.9 to €19.4 million. The optimal choice of IOL for cataract surgery offers the opportunity to reduce these costs. More research is warranted with respect to indirect costs associated with treating PCO.

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark

Code

PMD42

Topic

Clinical Outcomes, Economic Evaluation

Topic Subcategory

Clinical Outcomes Assessment

Disease

Medical Devices

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×